Health Catalyst Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Health Catalyst Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.9963 $ to 3.50 $ · Last price: 1.80 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Health Information Services
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Health Catalyst Inc HCAT | 0.1 | – | -5.0 | 51.2 | – | 1.5 | -35.9 |
| Veeva Systems Inc Class A VEEV | 41.1 | 44.0 | 33.4 | 75.0 | 30.9 | 16.3 | -3.9 |
| Tempus AI, Inc. TEM | 14.2 | – | 0.0 | 64.0 | -24.3 | 83.4 | -7.0 |
| BrightSpring Health Services, Inc. BTSG | 11.2 | 73.3 | 22.6 | 12.4 | 3.4 | 14.6 | 106.6 |
| 10X Genomics Inc TXG | 10.1 | – | 148.5 | 70.1 | -11.3 | 5.3 | 498.5 |
| HealthEquity Inc HQY | 7.9 | 39.6 | 16.8 | 71.3 | 29.3 | 9.5 | 2.4 |
| Hinge Health, Inc. HNGE | 7.6 | 11.9 | 71.9 | 84.5 | 19.0 | 50.6 | 59.2 |
| Doximity Inc DOCS | 4.8 | – | 18.7 | 88.1 | 21.6 | 13.1 | -63.4 |
| Waystar Holding Corp. WAY | 4.8 | – | 14.8 | 69.1 | 25.6 | 16.5 | -31.3 |
| Median of companies shown | 7.9 | 41.8 | 18.7 | 70.1 | 20.3 | 14.6 | -3.9 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 73 | -46 | -47 | -1.69 | -37 | -259 | 110 |
| 2018 | 113 | -60 | -62 | -2.23 | -40 | -375 | 111 |
| 2019 | 155 | -55 | -60 | -3.21 | -32 | 201 | 302 |
| 2020 | 189 | -96 | -115 | -2.91 | -26 | 276 | 578 |
| 2021 | 242 | -144 | -153 | -3.23 | -23 | 522 | 832 |
| 2022 | 276 | -140 | -137 | -2.54 | -35 | 425 | 752 |
| 2023 | 296 | -127 | -118 | -2.09 | -33 | 367 | 702 |
| 2024 | 307 | -70 | -70 | -1.15 | 15 | 365 | 859 |
| 2025 | 311 | -36 | -178 | -2.55 | 1 | 246 | 503 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.33 | – | 80 | 6.00 | -26.00 | -4 | -8 |
| 2025: Q1 | -0.35 | – | 79 | 6.30 | -29.90 | 0 | 0 |
| 2025: Q2 | -0.59 | – | 81 | 6.30 | -50.80 | -9 | -9 |
| 2025: Q3 | -0.32 | – | 76 | 0.00 | -29.10 | -1 | -5 |
| 2025: Q4 | -1.28 | – | 75 | -6.20 | -121.90 | 10 | 10 |
| 2026: Q1 | -1.53 | – | 71 | -10.90 | -156.90 | 19 | 14 |
| 2026: Q2 | -0.55 | 6.80 | 71 | -12.60 | -57.40 | 0 | 0 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.05 | -0.09 – 0.00 | 248 | -125.2% | 5 |
| 12/31/2027 | 0.01 | -0.12 – 0.10 | 208 | 117.3% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly -1.7% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $13.1M |
|---|---|
| Market cap | $132.0M |
| Free cash flow in year ten | $11.0M |
| Terminal value as a share of market value | 43.9% |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 4.0%
- More than 10% revenue growth is expected for the coming year -6.2%
- Share count grows by less than 3% a year 8.9%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1.4%
- Gross margin at 40% or higher and without meaningful erosion 33.5%
- Goodwill from acquisitions does not grow faster than revenue 41.6%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 348 m
- Return on capital at 15% or higher, or up versus two years ago -8.7%
- Insiders hold at least 10% or are net buyers 5.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 19.9%
- Exp. sales growth 3Y > 5% -18.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -18.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -8.7%
- Expected return > 10% -18.4%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Kohl Simeon | Chief Executive Officer | Buy | 59,000 | 1.79 | 105,439 |
| Sep 14, 2026 | Kohl Simeon | Chief Executive Officer | Other | 2,747,385 | 0.00 | – |
| Sep 10, 2026 | Albert Benjamin | CEO | Other | 35,244 | 1.67 | 59,023 |
| Sep 1, 2026 | Albert Benjamin | CEO | Other | 321 | 1.70 | 547 |
| Sep 1, 2026 | Landry Benjamin | General Counsel | Other | 13,167 | 1.70 | 22,431 |
| Sep 1, 2026 | Alger Jason | Chief Financial Officer | Other | 17,973 | 1.70 | 30,619 |
| Sep 1, 2026 | Larson-Green Julie | Director | Other | 9,766 | 0.00 | – |
| Jul 16, 2026 | Hoggard Green Jill | Director | Other | 80,691 | 0.00 | – |
| Jul 16, 2026 | Larson-Green Julie | Director | Other | 80,691 | 0.00 | – |
| Jul 16, 2026 | Spencer Justin | Director | Other | 80,691 | 0.00 | – |
The company
About the Company
Health Catalyst, Inc. bietet Datenanalyse-Technologie und -Dienstleistungen für Gesundheitsorganisationen in den USA an.
- Employees
- 1,200
- Headquarters
- South Jordan, UT
- Address
- 10897 South River Front Parkway, 84095 South Jordan, United States
- Phone
- 801 708 6800
- Website
- healthcatalyst.com
- IPO Date
- 07/25/2019
- ISIN
- US42225T1079
Management
| Name | Title | Birth Year |
|---|---|---|
| Benjamin Albert | CEO & Director | 1973 |
| Jason Alger | Chief Financial Officer | 1984 |
| Benjamin Landry | General Counsel & Secretary of the Board | 1982 |
| Kyle J. Salyers | Chief Strategy Officer & Senior VP of Corporate Development | – |
| Carrie Kozlowski OT | Chief Marketing Officer | – |
| Jeffrey P. Selander | Senior Vice President of International | – |
| Holly Rimmasch | Senior VP & Chief Clinical Officer | – |
| Sadiqa Mahmood D.D.S., M.P.H. | GM & Senior VP of Life Sciences Business | – |
| Kristen Berry | Senior Vice President of Public Relations | – |
| Ryan Barry | Chief Operating Officer of Professional Services | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 09/14/2026 Health Catalyst, Inc. (HCAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 09/08/2026 Health Catalyst, Inc. (HCAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/06/2026 Health Catalyst, Inc. (HCAT): Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 07/17/2026 Health Catalyst, Inc. (HCAT): Submission of Matters to a Vote of Security Holders SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.